Clinical trials
Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma clinical trials
Below are recruiting relapsed or refractory b-cell non-hodgkin lymphoma clinical trials, each written for real people, not researchers. We’re tracking 1,761 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06421675RecruitingPhase 2
Elranatamab for multiple myeloma that has come back
This trial tests a new drug called elranatamab (given as an outpatient, not in the hospital) for people with multiple myeloma that has come back or stopped responding to several treatments. The goal is to see if taking it less often works well and is safer.
Vancouver, British ColumbiaAges 18 years+ - NCT06427330RecruitingPhase 2
Low-Dose Inotuzumab After Transplant to Prevent Leukemia Relapse
This trial tests whether a low dose of a targeted drug called inotuzumab ozogamicin, given after a stem cell transplant, can help prevent acute lymphoblastic leukemia from coming back. It is for people who have already had a transplant and are at high risk for relapse.
TianjinAges 18 years+ - NCT06439199Recruiting
Blood protein study in non-intensive chemotherapy for AML and MDS
This study looks at certain proteins in the blood (called FLT3 ligand and IL6) of people being treated for blood cancers like AML, MDS, or CMML. The goal is to understand how these proteins change during non-intensive chemotherapy, which may help doctors better personalize treatment.
Nantes, Loire-AtlantiqueAges 18–99 - NCT06456827Recruiting
Bite force and bone changes after braces in different face types
This trial compares how bite force and bone turnover markers change during the retention phase (after braces) in people with high-angle and low-angle face types. It may help understand why some people have more relapse after braces.
Rohtak, HaryanaAges 18–45 - NCT06458244Recruiting
Stem cell transplant for high-risk CBF-AML
This trial tests a stem cell transplant (using donor cells) for people with a high-risk form of acute myeloid leukemia called CBF-AML. The goal is to see if this transplant can help patients who have a higher chance of the leukemia coming back.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06470321Recruiting
Predictors of nicotine relapse in smokers
This study looks at factors that might predict whether someone will start smoking again after quitting. It is for adults who smoke daily, want to quit, and are not on any medications.
NicosiaAges 18–60 - NCT06492954RecruitingPhase 1
Testing atezolizumab with radiation and surgery for lung-only osteosarcoma
This trial tests whether combining an immunotherapy drug (atezolizumab) with focused radiation and surgery can help people whose osteosarcoma has come back only in the lungs. It aims to see if this approach is safe and may improve outcomes.
Atlanta, GeorgiaAges Up to 50 years - NCT06497361RecruitingEarly Phase 1
PRG-2311 for hard-to-treat lupus nephritis and IgG4 disease
This trial tests a new treatment called PRG-2311 for people with lupus nephritis or IgG4-related disease that has not responded to standard therapies. The treatment uses a type of immune cell therapy (CAR-T) to try to control the disease.
Wuhan, HubeiAges 18 years+ - NCT06497387RecruitingEarly Phase 1
PRG-1801 for stubborn lupus kidney and IgG4 disease
This trial tests a new treatment called PRG-1801 for people with lupus nephritis (kidney inflammation from lupus) or IgG4-related disease that has not improved with standard treatments. The treatment uses your own immune cells to target and calm the disease.
Wuhan, HubeiAges 18 years+ - NCT06506149Recruiting
Microwave ablation for relapsed Graves' disease
This study tests if microwave ablation (a heat-based treatment) can help people whose Graves' disease returned after medication. It is a non-surgical option that may avoid lifelong medication or surgery.
Hong KongAges 18 years+ - NCT06508216RecruitingPhase 1/Phase 2
New drug combo for early relapsed triple-negative breast cancer
This trial tests experimental drugs for people with triple-negative breast cancer that came back within 12 months of finishing initial treatment. The goal is to see if these drugs are safe and can shrink or slow the cancer.
VillejuifAges 18 years+ - NCT06526364Recruiting
Multiple sclerosis study with smartphone app tracking
This study follows people with multiple sclerosis over time using a smartphone app and clinic visits. It aims to better understand the disease and improve care.
BaselAges 18 years+ - NCT06532084RecruitingPhase 2
Sorafenib to prevent relapse after stem cell transplant
This trial tests whether the drug sorafenib can prevent blood cancer from returning after a stem cell transplant. It is for people who had a special combination of chemotherapy (bendamustine and cyclophosphamide) during their transplant and are at high risk for relapse.
Saint PetersburgAges 18–75 - NCT06536413RecruitingPhase 1/Phase 2
ATRA and Carfilzomib for multiple myeloma
This trial tests if combining the drug ATRA with carfilzomib can help people with multiple myeloma whose cancer has come back or stopped responding to at least three prior treatments, including carfilzomib. The goal is to see if this new combination works better than carfilzomib alone.
Houston, TexasAges 18 years+ - NCT06543381RecruitingPhase 1
Olutasidenib for IDH1-mutated blood cancers after transplant
This trial tests a drug called olutasidenib for people with certain blood cancers (AML, MDS, or CMML) that have a specific IDH1 gene change. The goal is to see if it can help prevent relapse after a donor stem cell transplant.
Duarte, CaliforniaAges 18 years+ - NCT06552611RecruitingPhase 1
Spinal cord stimulation for hand function in MS
This study tests whether a gentle electrical stimulation applied to the skin over the spinal cord can help improve hand and arm function in people with MS. If you have MS and difficulty using your hands, you may be able to join.
Seattle, WashingtonAges 21–70 - NCT06561399Recruiting
Triple therapy followed by radiation for liver cancer
This trial tests whether adding targeted radiation therapy can help people with liver cancer that cannot be surgically removed. It is for people who have already received a combination of TACE, lenvatinib, and sintilimab and whose tumors have not grown.
Fuzhou, FujianAges 18–75 - NCT06561854RecruitingPhase 3
Comparing multiple myeloma treatment with and without dexamethasone
This trial tests whether adding dexamethasone to an antibody-based combination therapy works better for multiple myeloma that has come back after previous treatments. If you have had 1 to 3 prior therapies and are eligible for one of two standard drug regimens, this study may help find the best approach for you.
ParisAges 18 years+ - NCT06569550Recruiting
Fatigue treatment study for multiple sclerosis
This trial tests a brain stimulation therapy designed to reduce fatigue in people with multiple sclerosis. If you experience moderate to severe fatigue and have a stable medication routine, this study might help determine if a non-invasive treatment can improve your energy levels.
Hvidovre, Capital RegionAges 18–65 - NCT06575296RecruitingPhase 1
Revumenib after stem cell transplant for acute leukemia
This trial tests a drug called revumenib to help keep leukemia from coming back after a stem cell transplant. It is for people with specific genetic types of acute leukemia who have recently had or will soon have a transplant.
Duarte, CaliforniaAges 2 years+ - NCT06580574RecruitingPhase 2
Immunotherapy to save the stomach or colon from surgery
This trial tests whether using immune checkpoint inhibitors alone (like checkpoint blockade drugs) can help people with certain gastric or colon cancers avoid surgery. It's for patients whose tumors have a specific genetic feature called dMMR/MSI-H and haven't spread to other parts of the body.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07007195RecruitingEarly Phase 1
Smart smell app to help you quit smoking
This study tests a smartphone app that uses your sense of smell to help you quit smoking. You'll use nicotine replacement therapy (like patches or gum) and the app to avoid relapse.
Houston, TexasAges 18 years+ - NCT06609369RecruitingPhase 2
Sleep and smoking relapse study
This study tests whether improving sleep can help people quit smoking and avoid relapse. It uses brain scans, a quitting medication, and counseling.
New Haven, ConnecticutAges 18–65 - NCT06611280Recruiting
Deuterium imaging study for people with multiple sclerosis
This study uses a special MRI technique to look at how brain cells use energy in people with relapsing-remitting MS. It may help doctors better understand MS and guide future treatments.
Aarhus CAges 18–60
Hear when a new Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory b-cell non-hodgkin lymphoma?
- Yes. Clin2 currently lists 1,761 recruiting relapsed or refractory b-cell non-hodgkin lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory b-cell non-hodgkin lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory b-cell non-hodgkin lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.